Brokerages Set Humacyte, Inc. (NASDAQ:HUMA) Target Price at $11.00

Shares of Humacyte, Inc. (NASDAQ:HUMA) have received a consensus rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $13.00.

A number of brokerages have commented on HUMA. BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Thursday, November 21st. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. TD Cowen restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Finally, Benchmark restated a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research report on Thursday, October 10th.

Insider Transactions at Humacyte

In related news, CEO Laura E. Niklason sold 261,369 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the sale, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,014,998 shares of company stock valued at $9,725,449 in the last ninety days. 11.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently added to or reduced their stakes in HUMA. State Street Corp boosted its stake in shares of Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after purchasing an additional 1,895,529 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Humacyte by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock worth $11,101,000 after purchasing an additional 179,120 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Humacyte by 10.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock worth $3,924,000 after purchasing an additional 66,946 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Stock Up 3.5 %

HUMA stock opened at $4.43 on Friday. The company has a market cap of $557.56 million, a price-to-earnings ratio of -3.31 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. Humacyte has a 12 month low of $2.43 and a 12 month high of $9.97. The company has a fifty day moving average price of $5.28 and a 200 day moving average price of $6.19.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.